Open

Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP

To evaluate the efficacy of batoclimab compared to placebo in maintaining clinical response as assessed by adjusted inflammatory neuropathy cause and treatment (Adj INCAT) score in participants receiving immune globulin (IVIg or SCIg) or plasma exchange (PLEX) treatment for CIDP at the time of screening

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

Any side effects, overall health update, change in medications, willingness to continue study participation.

Incentives

Gas and or mileage reimbursement

In-person visits:
32

Phone or online visits:
48

Total length of participation:
25 months

Looking for Specific Volunteers

Able to participate:

Chronic Inflammatory demyelinating polyneuropathy

Not eligible if:

Have Polyneuropathy of causes other than CIDP
Poorly controlled Diabetes Mellitus
Recieving chronic corticosteroids
Pregnant or wishing to get pregnant

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Rebecca Traub
Neurology

Study Type

Clinical or Medical
Interventional

Study Topics

Brain, Head, Nervous System

IRB Number

24-0195

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.